Recently published research from GlobalData, "Epratuzumab (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022", is now available at Fast Market Research

Boston, MA -- (SBWire) -- 12/24/2013 --Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease. While SLE can affect multiple major organ systems in the body, one of its most severe manifestations includes renal (kidney) involvement, known as lupus nephritis (LN). The term LN refers to SLE patients with glomerulonephritis, and when the term LN is used, glomerular tissue injury in the kidneys is always involved. Renal injury without any glomerular involvement is classified as nephritis in a patient with SLE.

UCB is developing epratuzumab as a potential treatment for lupus. Epratuzumab was initially developed by Immunomedics and in May 2006 was licensed to UCB, with exclusive worldwide rights to develop and market epratuzumab for all autoimmune disease indications. Immunomedics has retained the rights to epratuzumab in oncology indications, for which UCB has been granted a buy-in option.

View Full Report Details and Table of Contents

Scope

- Overview of SLE-LN, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Epratuzumab including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Epratuzumab for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to Get This Report

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for SLE-LN
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Epratuzumab performance
- Obtain sales forecast for Epratuzumab from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Germany Drug Forecast and Market Analysis to 2022
- PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Spain Drug Forecast and Market Analysis to 2022
- PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Japan Drug Forecast and Market Analysis to 2022
- PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Italy Drug Forecast and Market Analysis to 2022
- PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - UK Drug Forecast and Market Analysis to 2022
- PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - US Drug Forecast and Market Analysis to 2022
- PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - France Drug Forecast and Market Analysis to 2022
- Lupuzor (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022
- Tabalumab (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022
- Blisibimod (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022